Skip to main content
Delfa

← Trials/Trial dossier/NCT00139373

UnknownPhase 2

Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy

Asset

Donepezil

Listed sites

1

Recruiting sites

1

Enrollment

16

estimated

Study population

Frontotemporal dementia

Key I/E criterion

•Age 30-80

Primary endpoint

-

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00139373
Org study IDRBM0323

Timeline

Milestones

Study first posted2005-08-31estimated
Last update posted2007-09-14estimated

Assets

Drug assets

Donepezil

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age30 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients with PSP
•Age > 30 years old
•Disease duration < 5 years
•Mini mental state (MMS) > 24
•Antisaccades %: 40-80%

Exclusion criteria

•Other parkinsonian syndromes
•MMS < 24

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.